
News|Slideshows|August 11, 2021
8 Questions on Diabetes Drugs for Cardioprotection
Author(s)Leo Robert
Advertisement
Cardioprotective effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) have been reported in a number of high-profile, landmark clinical trials.
Take this quick quiz to test your knowledge of key findings.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301
2
FDA Approves Xocova as First Oral COVID-19 Postexposure Prophylaxis Option
3
Pediatric Influenza Vaccination Linked to Fewer Diagnoses in Claims Study
4
Transdermal Hormone Therapy for VMS and Cardiovascular Risk Management
5

















































































































































